

How To Participate

REGISTRATION INSTRUCTIONS

- When you have selected your teleconference date/time, Web registration is available at: <https://reg.linkconferencecall.com/law>. Alternatively, call 203-323-5945.
- You must register at least 7 days prior to the date of the teleconference if you would like to receive a workbook. You can register at any time if you plan to view the PowerPoint presentation via the Web.
- An accurate mailing address is required to ensure receipt of your workbook.
- When you have registered, you will receive a toll-free number for the teleconference, as well as a Web URL that will allow you to access the content online.
- There is no registration fee for this program.

DAY OF THE TELECONFERENCE

- To connect with the teleconference, call the toll-free number within 10 minutes prior to the start of the activity.
- To view the PowerPoint slides online, type in the Web URL and follow the prompts to log into the TeleWeb session.

DURING THE TELECONFERENCE

- Refer to your workbook or the online PowerPoint session during the faculty presentation.
- Each 1-hour teleconference will include a live 40- to 45-minute presentation followed by a 15- to 20-minute question-and-answer session. Participants will be able to call in and ask questions, or send questions via the Internet.
- You are encouraged to ask questions of the faculty during the question-and-answer session following the presentation via phone or Web.
- In order to qualify for continuing education credit, you must participate (remain on the line) for the entire activity (1 hour).

CONTINUING EDUCATION CREDIT

- To receive continuing education credit, you must complete the evaluation and registration online.
- A statement of credit will be available for printing online upon completion of the evaluation.

PharmaCom Group, Inc.
76 Progress Drive
Stamford, CT 06902



December 2007
CME/CE Teleconference Series
A **LIVE** Interactive Program

Lawful Prescribing & Prevention of Diversion

A Balanced Approach to Controlled Substances



A Live Interactive Program

This activity is jointly sponsored by the



Dannemiller Memorial Educational Foundation

and



PharmaCom Group, Inc.

Target audience:
physicians, pharmacists, nurse practitioners, and nurses

PSRST STD
U.S. Postage
PAID
Utica, NY
Permit #566

Needs Statement

Pain is a common presenting complaint, and although most people do not need opioid analgesics, they may be required to relieve moderate and severe pain. It is therefore important for clinicians to identify when opioids might be useful, know how to prescribe them safely, and understand the regulatory structure that surrounds the controlled substances that are being prescribed. Because opioids also have a potential for abuse, these drugs are regulated pursuant to federal and state controlled substance policies, which are intended to prevent illicit trafficking and drug abuse. Although the US Congress has authorized the medically appropriate use of opioids in Schedule II of the Controlled Substances Act, and regulations are not intended or allowed to hinder legitimate medical practice, enforcement of the law is sometimes more complicated. Despite policy shifts legitimizing the treatment of persistent pain with opioids, this topic remains controversial, and federal and state professional and law enforcement authorities have investigated and, in some cases, disciplined physicians for what they have judged to be indiscriminate prescribing.

The media coverage of prescription drug abuse and the resulting uncertainty regarding potential disciplinary action has created a dilemma for prescribers and has heightened their fear of regulatory and legal sanction. While only a small number of physicians who prescribe opioids have been subject to legal scrutiny, more are investigated, and even this can have a chilling effect. This

uncertainty has given some clinicians pause when considering whether to accept a patient in chronic pain or how to treat a patient who may require long-term or high-dose opioids. At the same time, clinicians also run the risk of legal scrutiny for failure to adequately treat pain.

■ Goal

The goal of this teleconference is to review the laws and regulations governing controlled substance prescribing in the United States, and to provide clinicians with practical advice that will help them prescribe opioids safely, when indicated, and avoid substance abuse and drug diversion in their practices.

■ Learning Objectives

After completing this educational activity, participants should be better able to:

1. Explain the legitimate role of controlled substances for pain management; the problems surrounding misuse, abuse, and diversion; and the principle of balance
2. Be familiar with the federal regulations governing prescribing of controlled substances
3. Distinguish between addiction, physical dependence, tolerance, and pseudoaddiction
4. Formulate strategies to:
 - a. Optimize pain management
 - b. Lessen the possibility of diversion
 - c. Protect prescribing authority

Teleconference Faculty

David B. Brushwood, RPh, JD
Professor of Pharmacy Health Care Administration
University of Florida
Gainesville, FL

John Burke
President
National Association of Drug Diversion Investigators (NADDI)
Commander
Warren County Drug Task Force
Lebanon, OH

Perry G. Fine, MD
Professor of Anesthesiology
Pain Research Center, School of Medicine
University of Utah
Salt Lake City, UT

Steven D. Passik, PhD
Associate Professor of Psychology in Psychiatry
Weill Medical College of Cornell University
Associate Attending Psychologist
Department of Psychiatry & Behavioral Sciences
Memorial Sloan-Kettering Cancer Center
New York, NY

Jennifer P. Schneider, MD, PhD
Internal Medicine, Addiction Medicine, & Pain Management
Arizona Community Physicians
Tucson, AZ

Lynn R. Webster, MD
Medical Director
Lifetree Clinical Research & Pain Clinic
Salt Lake City, UT

Schedule

Day	Date	Time (EST)	Faculty*
Monday	December 3	7-8pm	Fine/Burke
Tuesday	December 4	12-1pm	Passik/Webster
Tuesday	December 4	3-4pm	Schneider/Fine
Wednesday	December 5	1-2pm	Brushwood/Fine
Wednesday	December 5	4-5pm	Webster/Brushwood
Thursday	December 6	12-1pm	Burke/Passik
Thursday	December 6	3-4pm	Schneider/Burke
Monday	December 10	7-8pm	Burke/Fine
Tuesday	December 11	1-2pm	Webster/Passik
Tuesday	December 11	4-5pm	Passik/Schneider
Wednesday	December 12	12-1pm	Fine/Schneider
Wednesday	December 12	3-4pm	Brushwood/Webster
Thursday	December 13	12-1pm	Passik/Brushwood
Thursday	December 13	3-4pm	Schneider/Burke
Tuesday	December 18	7-8pm	Brushwood/Webster

*The faculty for each teleconference may be subject to change.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Dannemiller Memorial Educational Foundation and PharmaCom Group. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Dannemiller Memorial Educational Foundation is an approved provider of the California Board of Registered Nursing. Provider approved by the California Board of Registered Nursing, Provider Number 4229 for 1.2 contact hours. RNs outside California must verify with their licensing agency for approval of this course.

If you have any questions regarding the teleconference, please call PharmaCom Group at 203-323-5945.

This program is pending approval with the American Academy of Nurse Practitioners.

Purdue University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a continuing education activity of Purdue, an equal access/equal opportunity university. To receive the 1 contact hour of continuing education credit, pharmacists must attend the entire program and complete all registration and evaluations at its conclusion. Program # 018-999-07-199-L04-P. A statement of credit will be available for printing online upon completion of the evaluation.



Faculty disclosures are indicated in the teleconference workbook and the online TeleWeb session.